A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
Recruiting now
Conditions studied: Atopic Dermatitis, Eczema
In brief
The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis. Atopic dermatitis, or AD, is a long-lasting disease that causes inflammation, redness, and irritation of the skin. This study is seeking participant who are older than 18 years with moderate-to-severe chronic AD. Participants must have no underlying medical conditions that prevent them from taking Abrocitinib. All participants in this study will receive Abrocitinib as a tablet once daily. They can take Abrocitinib and use medicated topical treatment for AD at the same time. We will examine the experiences of patients receiving the study medicine. This will help us determine if the study medicine is safe and helps in treating AD. Participants will take part in this study for 24 months. During this time, they will visit the study clinic about 5 times (about 1 time every 4 to 6 months).
Key facts
- Study ID
- NCT05689151
- Run by
- Pfizer
- People needed
- 183
- Starts
- 2023-03-09
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2026-07-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients older than 18 years of age at inclusion.
- Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator and eligible for abrocitinib according to its marketing approval.
- Patients that have been informed of the study procedures and have signed the consent.
You may not qualify if…
- Patients for whom abrocitinib is contraindicated.
- Patients unable to follow and respect the study procedures and judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons.
- Patients not affiliated to the French social security system.
- Patients deprived of liberty, under guardianship, or unable to provide oral consent.
- Patients participating in a clinical study assessing a medicinal treatment (patients can participate in registries and observatories).
Where it is running
- CHU Amiens-Picardie - Site Nord — Amiens, Somme, France (enrolling)
- CHU Besancon - Hopital Jean Minjoz — Besançon, France (enrolling)
- Polyclinique Reims Bezannes — Bezannes, France (enrolling)
- Chu Bordeaux Hopital Saint Andre — Bordeaux, France (enrolling)
- CHU Brest Hopital Morvan — Brest, France (enrolling)
- CHU de Caen — Caen, France (enrolling)
- Ch de Calais — Calais, France (enrolling)
- Ch William Morey — Chalon-sur-Saône, France (enrolling)
- CHU Clermont Ferrand - Hopital Gabriel Montpied — Clermont-Ferrand, France (enrolling)
- Chu Estaing — Clermont-Ferrand, France (enrolling)
- Hopital Henri Mondor — Créteil, France (enrolling)
- Chu Dijon — Dijon, France (enrolling)
- Hopital Franco Britannique — Levallois-Perret, France (enrolling)
- Hopital Claude Huriez — Lille, France (enrolling)
- CH de Martigues — Martigues, France (enrolling)
- CHU Montpellier — Montpellier, France (enrolling)
- Hopital Emile Muller — Mulhouse, France (enrolling)
- Hopital Hotel Dieu — Nantes, France (enrolling)
- Hopital Cochin — Paris, France (enrolling)
- Hopital Tenon — Paris, France (enrolling)
- Hopital Saint Louis (APHP) - Service Hematologic Senior — Paris, France (enrolling)
- CHU Lyon Sud — Pierre-Bénite, France (enrolling)
- Hopital Pontchaillou — Rennes, France (enrolling)
- Ch de Romans Sur Isere — Romans-sur-Isère, France (enrolling)
- Hopital Charles Nicolle — Rouen, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.